Alexion Halts Ultomiris Royalties to Xencor, Putting $100M+ Revenue at Risk
Summary
Xencor announced that its licensee, Alexion, has notified the company it will cease U.S. royalty payments for Ultomiris, asserting no further U.S. royalties are due. Xencor vehemently disputes Alexion's stance and is actively exploring options to resolve the conflict. This development places an estimated $100-120 million in aggregate U.S. royalties, previously expected through 2028, at significant risk. In light of this, Xencor has updated its year-end 2026 cash, cash equivalents, and marketable debt securities guidance to $380-400 million. While the company maintains it has sufficient cash to fund R&D and operations into mid-2028, the potential loss of this substantial revenue stream represents a material negative impact on future financial performance. Traders will closely monitor the progress and outcome of this royalty dispute.
At the time of this announcement, XNCR was trading at $12.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $934.3M. The 52-week trading range was $6.92 to $18.69. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.